Athersys (ATHX) 2.86 $ATHX
Athersys (ATHX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:50AM CDT
Athersys is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
ATHX: 2.86 (-0.06)
Date And Time Is Set For Athersys Phase II Stroke Presentation
Wall Street Titan - at Seeking Alpha - Thu Mar 26, 1:25PM CDT
ATHX: 2.86 (-0.06)
Athersys Down 5.7%, Shares Slide into the Red (ATHX)
Comtex SmarTrend(R) - Thu Mar 26, 11:48AM CDT
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 5.7% to $2.71 on 1.1x average daily volume. Athersys has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.1%) and underperformed the S&P 500 (-5.7% to the S&P's -0.1%) during today's trading.
ATHX: 2.86 (-0.06)
Why Athersys (ATHX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:57AM CDT
Athersys in the health care space is seeing solid activity on the earnings estimate revision front
ATHX: 2.86 (-0.06)
Athersys: An Ischemic Stroke Holy Grail? Find Out In Less Than A Month
Northern Fundamentals - at Seeking Alpha - Tue Mar 24, 4:00PM CDT
ATHX: 2.86 (-0.06)
ATHX SqueezeTrigger Price is $3.24. There is $8,225,835 That Short Sellers Still Need To Cover.
M2 - Tue Mar 24, 4:53AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Athersys Inc (NASDAQ:ATHX) in real time and just received an alert that ATHX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2426500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ATHX: 2.86 (-0.06)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 123.89 (+9.48), QURE: 25.17 (+0.08), SGMO: 15.86 (+0.32), JUNO: 60.66 (+4.06), ATHX: 2.86 (-0.06), NVS: 101.31 (+0.91)
Athersys to Participate at 12th Annual BIO Asia International Conference
GlobeNewswire - Thu Mar 19, 12:00PM CDT
Athersys, Inc. (Nasdaq:ATHX) announced today that it will be participating in the 12 annual BIO Asia International Conference to be held on March 24-25, 2015 at the Grand Hyatt, Tokyo, Japan. Athersys is additionally a conference sponsor.
ATHX: 2.86 (-0.06)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 35.00 (+0.47), ATHX: 2.86 (-0.06)
Athersys net loss imroves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:37AM CDT
ATHX: 2.86 (-0.06)
Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 6:34PM CDT
ATHX: 2.86 (-0.06)
Athersys reports 4Q loss
Automated Insights - Thu Mar 12, 3:45PM CDT
CLEVELAND (AP) _ Athersys Inc. (ATHX) on Thursday reported a loss of $6.6 million in its fourth quarter.
ATHX: 2.86 (-0.06)
Athersys (ATHX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 12, 3:25PM CDT
ATHX: 2.86 (-0.06)
Athersys beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:07PM CDT
ATHX: 2.86 (-0.06)
Athersys Reports Fourth Quarter and 2014 Annual Results
GlobeNewswire - Thu Mar 12, 3:05PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter and year ended December 31, 2014.
ATHX: 2.86 (-0.06)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:35PM CDT
ZUMZ: 40.18 (+1.12), KRO: 12.72 (+0.19), TEAR: 2.20 (-0.09), HIL: 3.58 (+0.08), OMED: 25.80 (-0.09), PPHM: 1.38 (unch), FXCM: 2.13 (-0.03), ARO: 3.33 (+0.03), EGY: 3.13 (-0.09), RMAX: 33.26 (+0.26), IRET: 7.52 (+0.05), IRG: 4.93 (-0.06), MED: 30.18 (+0.22), KTOS: 5.46 (-0.10), FTD: 30.41 (+0.16), LOCO: 25.81 (-0.16), ANAC: 56.81 (+1.96), ULTA: 151.58 (+0.38), ATHX: 2.86 (-0.06), FF: 10.34 (-0.48), GST: 2.69 (+0.07), JMBA: 14.87 (+0.12)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 10.51 (-3.38), OMED: 25.80 (-0.09), BIOA: 8.82 (-0.04), SUPN: 11.76 (-0.02), CTIC: 1.87 (+0.06), ALXA: 2.02 (+0.01), DSCI: 8.78 (+0.02), ANTH: 4.53 (+0.21), CYTX: 1.20 (+0.01), KYTH: 48.78 (+0.60), ANAC: 56.81 (+1.96), ATHX: 2.86 (-0.06), CRMD: 8.70 (+0.56), ACRX: 3.67 (-0.07), TROV: 7.00 (unch), ZGNX: 1.37 (+0.03), PETX: 16.53 (+0.28), RPRX: 8.54 (-0.03), IMUC: 0.50 (-0.01), PGNX: 5.82 (+0.03), SNTA: 2.33 (+0.03), BLCM: 22.65 (+0.19), TXMD: 6.20 (+0.20), OGXI: 2.13 (-0.02), AST: 7.05 (-0.42), PLX: 1.75 (-0.02), ATRS: 2.62 (+0.04)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 23.27 (+0.89), EBS: 29.18 (+0.66), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), AZN: 69.94 (-0.13), CCXI: 7.45 (+0.22), ATHX: 2.86 (-0.06), CELGZ: 2.81 (-0.22)
Athersys Up 12.7%, Shares Break Through Resistance (ATHX)
Comtex SmarTrend(R) - Mon Mar 02, 10:07AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 12.7% to $2.92 on 5.4x average daily volume. Thus far today, Athersys has traded 4.5 million shares, vs. average volume of 835,000 shares per day. The stock has outperformed the Dow (12.7% to the Dow's 0.7%) and outperformed the S&P 500 (12.7% to the S&P's 0.4%) during today's trading.
ATHX: 2.86 (-0.06)
Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data
at The Street - Mon Mar 02, 8:38AM CST
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
ATHX: 2.86 (-0.06)
Athersys (ATHX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:50AM CDT
Athersys is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
ATHX: 2.86 (-0.06)
Date And Time Is Set For Athersys Phase II Stroke Presentation
Wall Street Titan - at Seeking Alpha - Thu Mar 26, 1:25PM CDT
ATHX: 2.86 (-0.06)
Athersys Down 5.7%, Shares Slide into the Red (ATHX)
Comtex SmarTrend(R) - Thu Mar 26, 11:48AM CDT
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 5.7% to $2.71 on 1.1x average daily volume. Athersys has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.1%) and underperformed the S&P 500 (-5.7% to the S&P's -0.1%) during today's trading.
ATHX: 2.86 (-0.06)
Why Athersys (ATHX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:57AM CDT
Athersys in the health care space is seeing solid activity on the earnings estimate revision front
ATHX: 2.86 (-0.06)
Athersys: An Ischemic Stroke Holy Grail? Find Out In Less Than A Month
Northern Fundamentals - at Seeking Alpha - Tue Mar 24, 4:00PM CDT
ATHX: 2.86 (-0.06)
ATHX SqueezeTrigger Price is $3.24. There is $8,225,835 That Short Sellers Still Need To Cover.
M2 - Tue Mar 24, 4:53AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Athersys Inc (NASDAQ:ATHX) in real time and just received an alert that ATHX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 2426500 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ATHX: 2.86 (-0.06)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 123.89 (+9.48), QURE: 25.17 (+0.08), SGMO: 15.86 (+0.32), JUNO: 60.66 (+4.06), ATHX: 2.86 (-0.06), NVS: 101.31 (+0.91)
Athersys to Participate at 12th Annual BIO Asia International Conference
GlobeNewswire - Thu Mar 19, 12:00PM CDT
Athersys, Inc. (Nasdaq:ATHX) announced today that it will be participating in the 12 annual BIO Asia International Conference to be held on March 24-25, 2015 at the Grand Hyatt, Tokyo, Japan. Athersys is additionally a conference sponsor.
ATHX: 2.86 (-0.06)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 35.00 (+0.47), ATHX: 2.86 (-0.06)
Athersys net loss imroves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:37AM CDT
ATHX: 2.86 (-0.06)
Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 6:34PM CDT
ATHX: 2.86 (-0.06)
Athersys reports 4Q loss
Automated Insights - Thu Mar 12, 3:45PM CDT
CLEVELAND (AP) _ Athersys Inc. (ATHX) on Thursday reported a loss of $6.6 million in its fourth quarter.
ATHX: 2.86 (-0.06)
Athersys (ATHX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 12, 3:25PM CDT
ATHX: 2.86 (-0.06)
Athersys beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:07PM CDT
ATHX: 2.86 (-0.06)
Athersys Reports Fourth Quarter and 2014 Annual Results
GlobeNewswire - Thu Mar 12, 3:05PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter and year ended December 31, 2014.
ATHX: 2.86 (-0.06)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:35PM CDT
ZUMZ: 40.18 (+1.12), KRO: 12.72 (+0.19), TEAR: 2.20 (-0.09), HIL: 3.58 (+0.08), OMED: 25.80 (-0.09), PPHM: 1.38 (unch), FXCM: 2.13 (-0.03), ARO: 3.33 (+0.03), EGY: 3.13 (-0.09), RMAX: 33.26 (+0.26), IRET: 7.52 (+0.05), IRG: 4.93 (-0.06), MED: 30.18 (+0.22), KTOS: 5.46 (-0.10), FTD: 30.41 (+0.16), LOCO: 25.81 (-0.16), ANAC: 56.81 (+1.96), ULTA: 151.58 (+0.38), ATHX: 2.86 (-0.06), FF: 10.34 (-0.48), GST: 2.69 (+0.07), JMBA: 14.87 (+0.12)
Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 10.51 (-3.38), OMED: 25.80 (-0.09), BIOA: 8.82 (-0.04), SUPN: 11.76 (-0.02), CTIC: 1.87 (+0.06), ALXA: 2.02 (+0.01), DSCI: 8.78 (+0.02), ANTH: 4.53 (+0.21), CYTX: 1.20 (+0.01), KYTH: 48.78 (+0.60), ANAC: 56.81 (+1.96), ATHX: 2.86 (-0.06), CRMD: 8.70 (+0.56), ACRX: 3.67 (-0.07), TROV: 7.00 (unch), ZGNX: 1.37 (+0.03), PETX: 16.53 (+0.28), RPRX: 8.54 (-0.03), IMUC: 0.50 (-0.01), PGNX: 5.82 (+0.03), SNTA: 2.33 (+0.03), BLCM: 22.65 (+0.19), TXMD: 6.20 (+0.20), OGXI: 2.13 (-0.02), AST: 7.05 (-0.42), PLX: 1.75 (-0.02), ATRS: 2.62 (+0.04)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 23.27 (+0.89), EBS: 29.18 (+0.66), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), AZN: 69.94 (-0.13), CCXI: 7.45 (+0.22), ATHX: 2.86 (-0.06), CELGZ: 2.81 (-0.22)
Athersys Up 12.7%, Shares Break Through Resistance (ATHX)
Comtex SmarTrend(R) - Mon Mar 02, 10:07AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 12.7% to $2.92 on 5.4x average daily volume. Thus far today, Athersys has traded 4.5 million shares, vs. average volume of 835,000 shares per day. The stock has outperformed the Dow (12.7% to the Dow's 0.7%) and outperformed the S&P 500 (12.7% to the S&P's 0.4%) during today's trading.
ATHX: 2.86 (-0.06)
Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data
at The Street - Mon Mar 02, 8:38AM CST
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
ATHX: 2.86 (-0.06)
